Olivier Dormond

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


66 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
 
Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
Faes S., Santoro T., Troquier L., De Souza Silva O., Dormond O., 2019/06/04. Biochemical and biophysical research communications, 513 (3) pp. 546-552. Peer-reviewed.
 
mTOR in Human Diseases.
Dormond O., 2019/05/11. International journal of molecular sciences, 20 (9). Peer-reviewed.
 
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma.
Zoetemelk M., Rausch M., Colin D.J., Dormond O., Nowak-Sliwinska P., 2019/05/08. Scientific reports, 9 (1) p. 7103. Peer-reviewed.
 
Hypermobile Ehlers-Danlos-like syndrome in Fabry disease.
Barbey F., Lidove O., Dormond O., 2019/05. Clinical genetics, 95 (5) pp. 627-628. Peer-reviewed.
mTOR and Tumor Cachexia.
Duval A.P., Jeanneret C., Santoro T., Dormond O., 2018/07/30. International journal of molecular sciences, 19 (8) pp. pp17. Peer-reviewed.
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
Faes S., Santoro T., Demartines N., Dormond O., 2017/11/01. Cancers, 9 (11) pp. NA. Peer-reviewed.
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.
Uldry E., Faes S., Demartines N., Dormond O., 2017/06/30. International journal of molecular sciences, 18 (7) pp. 1-16. Peer-reviewed.
Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy.
Monney P., Qanadli S.D., Hajdu S., Tran C., Schwitter J., Dormond O., Barbey F., 2017. Swiss medical weekly, 147 pp. w14517. Peer-reviewed.
Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study.
Franzen D.P., Nowak A., Haile S.R., Mottet D., Bonani M., Dormond O., Kohler M., Krayenbuehl P.A., Barbey F., 2017. PloS one, 12 (7) pp. e0180437. Peer-reviewed.
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.
Faes S., Demartines N., Dormond O., 2017. Oxidative medicine and cellular longevity, 2017 p. 1726078. Peer-reviewed.
Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.
Faes S., Uldry E., Planche A., Santoro T., Pythoud C., Demartines N., Dormond O., 2016/12/27. Oncotarget, 7 (52) pp. 86026-86038. Peer-reviewed.
Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
Faes S., Duval A.P., Planche A., Uldry E., Santoro T., Pythoud C., Stehle J.C., Horlbeck J., Letovanec I., Riggi N. et al., 2016/12/05. Molecular cancer, 15 (1) p. 78. Peer-reviewed.
 
Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model.
Bize P., Duran R., Fuchs K., Dormond O., Namur J., Decosterd L.A., Jordan O., Doelker E., Denys A., 2016/08. Radiology, 280 (2) pp. 425-435. Peer-reviewed.
Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
Faes S., Planche A., Uldry E., Santoro T., Pythoud C., Stehle J.C., Horlbeck J., Letovanec I., Riggi N., Datta D. et al., 2016/06/14. Oncotarget, 7 (24) pp. 36666-36680. Peer-reviewed.
Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells.
Scholz G., Jandus C., Zhang L., Grandclément C., Lopez-Mejia I.C., Soneson C., Delorenzi M., Fajas L., Held W., Dormond O. et al., 2016. Ebiomedicine, 4 pp. 50-61. Peer-reviewed.
DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport.
Bernier-Latmani J., Cisarovsky C., Demir C.S., Bruand M., Jaquet M., Davanture S., Ragusa S., Siegert S., Dormond O., Benedito R. et al., 2015. Journal of Clinical Investigation, 2015 pp. 4572-4586. Peer-reviewed.
PI3K and AKT: Unfaithful Partners in Cancer.
Faes S., Dormond O., 2015. International Journal of Molecular Sciences, 16 (9) pp. 21138-21152. Peer-reviewed.
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.
Weiss A., Ding X., van Beijnum J.R., Wong I., Wong T.J., Berndsen R.H., Dormond O., Dallinga M., Shen L., Schlingemann R.O. et al., 2015. Angiogenesis, 18 (3) pp. 233-244. Peer-reviewed.
Systemic Buffers in Cancer Therapy: The Example of Sodium Bicarbonate; Stupid Idea or Wise Remedy?
Faes Seraina, Dormond Olivier, 2015. Medicinal Chemistry, 5 (12) pp. 540-544. Peer-reviewed.
 
Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance.
Singh A.K., Arya R.K., Maheshwari S., Singh A., Meena S., Pandey P., Dormond O., Datta D., 2015. International Journal of Cancer. Journal International Du Cancer, 136 (9) pp. 1991-2000. Peer-reviewed.
 
Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model.
Fuchs K., Bize P.E., Dormond O., Denys A., Doelker E., Borchard G., Jordan O., 2014. Journal of Vascular and Interventional Radiology, 25 (3) pp. 379-87, 387.e1-2. Peer-reviewed.
 
PGE2-induced colon cancer growth is mediated by mTORC1.
Dufour M., Faes S., Dormond-Meuwly A., Demartines N., Dormond O., 2014. Biochemical and Biophysical Research Communications, 451 (4) pp. 587-591. Peer-reviewed.
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
Singh A.K., Arya R.K., Trivedi A.K., Sanyal S., Baral R., Dormond O., Briscoe D.M., Datta D., 2013. Cytokine and Growth Factor Reviews, 24 (1) pp. 41-49. Peer-reviewed.
 
Evaluation of the antitumoral effect sunitinib eluting beads in VX2 liver tumour in a rabbit model.
Bize P., Jordan O., Fuchs K., Dormond O., Duran R., Doelker E., De Baere T., Denys A., 2013. pp. Abstract 247 dans 2013 Gastrointestinal Cancers Symposium, Journal of Clinical Oncology.
 
In vitro and in vivo evaluation of sunitinib eluting beads
Bize P., Jordan O., Fuchs K., Dormond O., Duran R., Doelker E., De Baere T., Denys A., 2013. pp. Abstract 246 dans 2013 Gastrointestinal Cancers Symposium, Journal of Clinical Oncology.
 
Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.
Dufour M., Dormond-Meuwly A., Pythoud C., Demartines N., Dormond O., 2013. Biochemical and Biophysical Research Communications, 438 (1) pp. 32-37. Peer-reviewed.
 
Thoracic aortic dilation/aneurysm in fabry disease.
Dormond O., Barbey F., 2013. American Journal of Medicine, 126 (12) pp. e23.
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Blaser B., Waselle L., Dormond-Meuwly A., Dufour M., Roulin D., Demartines N., Dormond O., 2012. BMC Cancer, 12 p. 86.
 
In vivo characterization of sunitinib eluting beads
Bize P., Jordan O., Dormond O., Duran R., Doelker E., De Baere T., Denys A., 2012. dans SIR 2012, 37th Annual Meeting of the Society of Interventional Radiology.
 
In vivo evaluation of sunitinib-loaded DC Bead
Bize P., Jordan O., Dormond O., Duran R., Doelker E., de Baere T., Denys A., 2012. dans CIRSE 2012, Annual Congress and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe.
 
In vivo evaluation of the anti-tumoral effect of sunitinib eluting beads in the rabbit VX2 tumor model
Bize P., Jordan O., Dormond O., Duran R., Doelker E., De Baere T., Denys A., 2012. dans SIR 2012, 37th Annual Meeting of the Society of Interventional Radiology.
 
In vivo evaluation of the anti-tumoral effect of sunitinib-eluting beads in the rabbit VX2 tumor model
Bize P., Jordan O., Dormond O., Duran R., Doelker E., de Baere T., Denys A., 2012. dans CIRSE 2012, Annual Congress and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe.
 
In-Vitro Study of DC Beads Loaded with Sunitinib
Fuchs C., Siegrfied C., Denys A., Bize P., Dormond O., Doelker E., Borchard G., Jordan O., 2012. dans GEST 2012, Global Embolization Symposium and Technolgies.
 
In-Vivo Pharmacokinetics of DC-Beads Loaded with Sunitinib in an Animal Model
Bize P., Jordan O., Dormond O., Duran R., Doelker E., De Baere T., Denys A., 2012. dans GEST 2012, Global Embolization Symposium and Technolgies.
 
Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation.
Sabine A., Agalarov Y., Maby-El Hajjami H., Jaquet M., Hägerling R., Pollmann C., Bebber D., Pfenniger A., Miura N., Dormond O. et al., 2012. Developmental Cell, 22 (2) pp. 430-445.
 
mTOR Inhibition and the Tumor Vasculature
Dormond-Meuwly A., Dufour M., Demartines N., Dormond O., 2012. Current Angiogenesis, 1 (1) pp. 11-19.
 
mTORC2 is an important signaling intermediary in VEGF-mediated endothelial cell proliferation, survival and migration
Dufour M., Dormond-Meuwly A., Demartines N., Dormond O., 2012. p. 19 dans 99th Annual Congress of the Swiss Society of Surgery, British Journal of Surgery.
Sunitinib-loaded microspheres for transarterial chemoembolization: in vitro drug release and pharmacokinetic profile in rabbits
Fuchs C., Siegrfied C., Denys A., Bize P., Dormond O., Doelker E., Borchard G., Jordan O., 2012. dans CRS German Chapter Annual Meeting, Focus on Controlled Release Systems for Proteins and Small Molecules.
 
Sunitinib-loaded microspheres for transarterial embolization : in vitro drug release and pharamacokinetic profile in rabbits.
Fuchs C., Siegrfied C., Denys A., Bize P., Dormond O., Doelker E., Borchard G., Jordan O., 2012. dans CRS2012, German Chapter Annual Meeting, Focus on Controlled release systems for proteins and small molecules.
Targeting the intragraft microenvironment and the development of chronic allograft rejection.
Dormond O., Dufour M., Seto T., Bruneau S., Briscoe D.M., 2012. Human Immunology, 73 (12) pp. 1261-1268. Peer-reviewed.
 
ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D., Demartines N., Dormond O., 2011. Biochemical Society Transactions, 39 (2) pp. 492-494.
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O., 2011. Molecular Cancer, 10 pp. -.
 
Targeting the JNK Signaling Pathway Potentiates the Antiproliferative Efficacy of Rapamycin in LS174T Colon Cancer Cells.
Benoit M., Dormond-Meuwly A., Demartines N., Dormond O., 2011. Journal of Surgical Research, 167 (2) pp. e193-e198.
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
Dufour M., Dormond-Meuwly A., Demartines N., Dormond O., 2011. Cancers, 3 (2) pp. 2478-2500. Peer-reviewed.
 
The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A., Roulin D., Dufour M., Benoit M., Demartines N., Dormond O., 2011. Biochemical and Biophysical Research Communications, 407 (4) pp. 714-719.
Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.
Brakch N., Dormond O., Bekri S., Golshayan D., Correvon M., Mazzolai L., Steinmann B., Barbey F., 2010. European Heart Journal, 31 (1) pp. 67-76.
 
Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.
Abdelnour-Berchtold E., Cerantola Y., Roulin D., Dormond-Meuwly A., Demartines N., Dormond O., 2010. Anticancer Research, 30 (3) pp. 799-804.
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.
Roulin D., Cerantola Y., Dormond-Meuwly A., Demartines N., Dormond O., 2010. Molecular Cancer, 9 p. 57. Peer-reviewed.
 
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.
Datta D., Contreras A.G., Basu A., Dormond O., Flynn E., Briscoe D.M., Pal S., 2009. Cancer Research, 69 (23) pp. 8902-9. Peer-reviewed.
 
CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O., Contreras A.G., Meijer E., Datta D., Flynn E., Pal S., Briscoe D.M., 2008. Journal of Immunolog, 181 (11) pp. 8088-8095.
 
mTOR-understanding the clinical effects.
Contreras A.G., Dormond O., Edelbauer M., Calzadilla K., Hoerning A., Pal S., Briscoe D.M., 2008. Transplantation Proceedings, 40 (10 Suppl.) pp. S9-S12.
 
mTORC2 regulates PGE2-mediated endothelial cell survival and migration.
Dada S., Demartines N., Dormond O., 2008. Biochemical and Biophysical Research Communications, 372 (4) pp. 875-879.
 
Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells.
Datta D., Dormond O., Basu A., Briscoe D.M., Pal S., 2007. American Journal of Physiology. Renal Physiology, 293 (4) pp. F1222-F1230.
 
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.
Dormond O., Madsen J.C., Briscoe D.M., 2007. Journal of Biological Chemistry, 282 (32) pp. 23679-23686.
 
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy - Invited commentary
Dormond O., Madsen J.C., 2006. Annals of Thoracic Surgery, 81 (5) pp. 1736-1737.
 
Images in emergency medicine. Giant pulmonary bulla.
Guyot E., Dormond O., 2005. Annals of Emergency Medicine, 45 (6) pp. 586, 591.
 
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C., Dormond O., Mariotti A., 2004. Biophysica Acta-Reviews on Cancer, 1654 (1) pp. 51-67. Peer-reviewed.
 
Manganese-induced integrin affinity maturation promotes recruitment of alpha V beta 3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src.
Dormond O., Ponsonnet L., Hasmim M., Foletti A., Rüegg C., 2004. Thrombosis and Haemostasis, 92 (1) pp. 151-161.
 
Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A.
Dormond O., Rüegg C., 2003. Thrombosis and Haemostasis, 90 (4) pp. 577-585.
 
Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
Bezzi M., Hasmim M., Bieler G., Dormond O., Rüegg C., 2003. Journal of Biological Chemistry, 278 (44) pp. 43603-43614. Peer-reviewed.
 
Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma.
Dormond O., Lejeune F.J., Ruegg C., 2002. Anticancer Research, 22 (6A) pp. 3159-3163.
 
Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling.
Dormond O., Bezzi M., Mariotti A., Ruegg C., 2002. Journal of Biological Chemistry, 277 (48) pp. 45838-45846. Peer-reviewed.
 
Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
Rüegg C., Dormond O., Foletti A., 2002. Endothelium, 9 (3) pp. 151-160.
 
NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
Dormond O., Foletti A., Paroz C., Rüegg C., 2001. Nature Medicine, 7 (9) pp. 1041-1047.
 
Suppression of tumor angiogenesis by nonsteroidal anti-inflammatory drugs: a new function for old drugs.
Rüegg C., Dormond O., 2001. Scientific World Journal, 1 pp. 808-811.
 
Tumor necrosis factor: clinical use and mechanisms of action
Rüegg C, Dormond O., Oguey D., Lejeune F.J., 2000. Drug Resistance Updates, 3 (5) pp. 271-276.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University